Non-invasive and blood-based
A serum-based assessment requiring a routine venous blood sample collected through the approved workflow.
Loading page
SeroMark-1 is a non-invasive, blood-based biomarker test designed to provide additional molecular insight alongside PSA and support informed clinical decisions about prostate cancer risk assessment.
Designed for informed clinical evaluation, not standalone diagnosis.
SeroMark-1 analyzes specific serum phospholipid patterns associated with prostate cancer and integrates multiple biomarker signals through a predictive model to generate a structured risk index.
A serum-based assessment requiring a routine venous blood sample collected through the approved workflow.
Multiple serum phospholipid signals are integrated into a consolidated prostate cancer risk assessment.
Biomarker patterns are processed through a statistical model to generate an objective risk index for clinical interpretation.
The assay is designed to evaluate disease-associated phospholipid patterns beyond a single biomarker measurement.
The medical visuals supplied in the SeroMark-1 professional brochure illustrate the disease context, biomarker science, laboratory analysis, clinical assessment, and doctor-led pathways.
SeroMark-1 should be integrated with established clinical information. It is not positioned as a replacement for PSA, examination, imaging, biopsy, or professional judgement.
The pathway connects sample integrity, targeted biomarker profiling, predictive analysis, structured reporting, and doctor-led decision-making.
Confirm that the patient meets the current approved suitability and preparation criteria.
Collect and route the fasting venous blood sample using the approved identification, handling, and transport protocol.
Evaluate the serum phospholipid biomarker pattern with laboratory quality-control safeguards.
Integrate multiple biomarker signals to generate the structured SeroMark-1 risk index.
Interpret the report alongside the full clinical context and determine the appropriate next step.
Each band requires correlation with the patient's age, history, PSA, examination findings, and other clinically appropriate information.
0.00–0.34
Review within the clinical context and continue the individualized screening or follow-up plan.
0.35–0.49
Correlate with PSA, history, examination, and other findings before determining the next step.
0.50–1.00
Prompt clinical review may be appropriate to decide whether further diagnostic evaluation is indicated.
The risk index is an aid to clinical assessment. It must not be used as the sole basis for diagnosis or treatment decisions.
Public and professional communication should remain aligned with the documented evidence, intended use, and current regulatory status.
Contact the team for current clinical documentation, sample requirements, collection coordination, laboratory collaboration, or professional onboarding.